BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22221634)

  • 21. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
    Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
    Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007.
    Dinan MA; Curtis LH; Carpenter WR; Biddle AK; Abernethy AP; Patz EF; Schulman KA; Weinberger M
    Radiology; 2013 Jun; 267(3):807-17. PubMed ID: 23418003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial.
    Yi CA; Lee KS; Lee HY; Kim S; Kwon OJ; Kim H; Choi JY; Kim BT; Hwang HS; Shim YM
    Cancer; 2013 May; 119(10):1784-91. PubMed ID: 23423920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Magnetic Resonance Imaging for N-Staging in Patients with Non-Small Cell Lung Cancer. A Systematic Review.
    Brea TP; Raviña AR; Villamor JMC; Gómez AG; de Alegría AM; Valdés L
    Arch Bronconeumol (Engl Ed); 2019 Jan; 55(1):9-16. PubMed ID: 29803524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer.
    Kubota K; Matsuno S; Morioka N; Adachi S; Koizumi M; Seto H; Kojo M; Nishioka S; Nishimura M; Yamamoto H
    Ann Nucl Med; 2015 Jun; 29(5):431-41. PubMed ID: 25812534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of whole-body PET imaging in non-small cell lung cancer and malignant melanoma.
    von Schulthess GK; Steinert HC; Dummer R; Weder W
    Acad Radiol; 1998 Sep; 5 Suppl 2():S300-2. PubMed ID: 9750837
    [No Abstract]   [Full Text] [Related]  

  • 27. PET/CT in oncology: for which tumours is it the reference standard?
    Collins CD
    Cancer Imaging; 2007 Oct; 7 Spec No A(Special issue A):S77-87. PubMed ID: 17921085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging modalities for the staging of patients with colorectal cancer.
    Bipat S; Niekel MC; Comans EF; Nio CY; Bemelman WA; Verhoef C; Stoker J
    Neth J Med; 2012 Jan; 70(1):26-34. PubMed ID: 22271811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
    Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
    J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis.
    Shen G; Deng H; Hu S; Jia Z
    Skeletal Radiol; 2014 Nov; 43(11):1503-13. PubMed ID: 24841276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The current status of positron emission tomography.
    Digby W; Keppler J
    Radiol Manage; 2000; 22(1):37-40. PubMed ID: 10787760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study.
    Paspulati RM; Partovi S; Herrmann KA; Krishnamurthi S; Delaney CP; Nguyen NC
    Abdom Imaging; 2015 Aug; 40(6):1415-25. PubMed ID: 26112492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contrast-enhanced PET/MR imaging versus contrast-enhanced PET/CT in head and neck cancer: how much MR information is needed?
    Kuhn FP; Hüllner M; Mader CE; Kastrinidis N; Huber GF; von Schulthess GK; Kollias S; Veit-Haibach P
    J Nucl Med; 2014 Apr; 55(4):551-8. PubMed ID: 24491410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endoscopic ultrasonography in esophageal cancer leads to improved survival rates: results from a population-based study.
    Wani S; Das A; Rastogi A; Drahos J; Ricker W; Parsons R; Bansal A; Yen R; Hosford L; Jankowski M; Sharma P; Cook MB
    Cancer; 2015 Jan; 121(2):194-201. PubMed ID: 25236485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
    Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
    Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer.
    Min JW; Um SW; Yim JJ; Yoo CG; Han SK; Shim YS; Kim YW
    J Korean Med Sci; 2009 Apr; 24(2):275-80. PubMed ID: 19399270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for brain metastases in patients with stage III non-small cell lung cancer: Is there additive value of magnetic resonance imaging above a contrast-enhanced computed tomography of the brain?
    Hendriks LE; Bootsma GP; de Ruysscher DK; Scheppers NA; Hofman PA; Brans BT; Dingemans AM
    Lung Cancer; 2013 Jun; 80(3):293-7. PubMed ID: 23518381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thoracic staging with
    Schaarschmidt BM; Grueneisen J; Metzenmacher M; Gomez B; Gauler T; Roesel C; Heusch P; Ruhlmann V; Umutlu L; Antoch G; Buchbender C
    Eur Radiol; 2017 Feb; 27(2):681-688. PubMed ID: 27180186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.